Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Talicabtagene autoleucel |
| Synonyms | |
| Therapy Description |
Talicabtagene autoleucel comprises T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) that targets CD19 and contains a 4-1BB (TNFRSF9) costimulatory domain, which potentially inhibit growth of CD19-expressing tumors (PMID: 40274761). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Talicabtagene autoleucel | Tali-cel|HCAR19|HCAR-19 | CD19 Immune Cell Therapy 76 | Talicabtagene autoleucel comprises T-lymphocytes that have been engineered to express a chimeric antigen receptor (CAR) that targets CD19 and contains a 4-1BB (TNFRSF9) costimulatory domain, which potentially inhibit growth of CD19-expressing tumors (PMID: 40274761). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07502118 | Phase II | Talicabtagene autoleucel | NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) (NexCAR19) | Recruiting | TUR | 0 |